Isomorphic Labs Raises $2.1 Billion Series B to Scale AI Drug Design Engine

--- headline: "Isomorphic Labs Raises $2.1 Billion Series B to Scale AI Drug Design Engine" slug: isomorphic-labs-2b-series-b-drug-design category: business story_number: "01" date: 2026-05-12 ---

# Isomorphic Labs Raises $2.1 Billion Series B to Scale AI Drug Design Engine

Isomorphic Labs, the Alphabet-backed AI drug discovery company founded by Nobel laureate Sir Demis Hassabis, has closed a $2.1 billion Series B financing round -- one of the largest private raises ever in the AI-for-biology space -- as it races to push AI-designed drug candidates into clinical trials before the end of 2026.

The round, announced on May 12, was led by Thrive Capital, with participation from existing investors Alphabet and GV alongside new backers MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The fresh capital brings Isomorphic Labs' total funding base to roughly $2.6 billion, cementing it as one of the best-capitalized startups at the intersection of artificial intelligence and pharmaceuticals.

Building the AI Drug Design Engine

At the heart of Isomorphic Labs' pitch is its proprietary AI Drug Design Engine, known internally as IsoDDE, a unified platform of foundational AI models trained to work across multiple therapeutic areas and drug modalities. Rather than applying AI to a single step in the drug discovery pipeline, IsoDDE aims to reimagine the entire process -- from target identification through molecular design and optimization -- as an integrated computational discipline.

The company recently published research demonstrating a subset of IsoDDE's capabilities, highlighting predictive accuracy that the company says bridges the gap between computational structure prediction and real-world drug discovery. In practical terms, the engine is designed to identify viable drug candidates with what Isomorphic describes as unprecedented speed and repeatable precision.

"This milestone is built on the strength of our AI drug design engine, which has already proven its worth across our internal programs by hitting key milestones and identifying viable candidates with unprecedented speed," said Max Jaderberg, President of Isomorphic Labs. "Our drug design engine works, and it's giving us a repeatable way to design new medicines for a wide range of diseases."

Where the Money Goes

The $2.1 billion will be directed toward three priorities: scaling the IsoDDE platform, expanding the company's pipeline of therapeutic programs toward the clinic, and hiring top talent across AI, engineering, drug design, and clinical disciplines at its offices in London, Cambridge (Massachusetts), and Lausanne (Switzerland).

Isomorphic Labs also maintains strategic partnerships with pharmaceutical heavyweights Novartis, Eli Lilly, and Johnson and Johnson -- collaborations that serve as external validation of its AI-first approach and provide additional channels for getting AI-designed molecules into development.

Ruth Porat, President and Chief Investment Officer at Alphabet and Google, emphasized the opportunity at stake. "Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform," she said. "This funding will be used to accelerate the work and bring important interventions to market with greater speed."

Joshua Kushner, Founder and CEO of lead investor Thrive Capital, added that over the past year his firm's conviction in the team had deepened, calling them the group best positioned to "define a new age of drug discovery and design."

Why This Matters

The sheer size of this round signals a broader shift in how capital markets are evaluating AI-native biotech companies. Traditional drug discovery is notoriously expensive -- industry estimates peg the average cost of bringing a single drug to market at $1 billion to $2.6 billion over a decade or more. If AI can meaningfully compress timelines and reduce failure rates, the economic implications are enormous.

Isomorphic Labs is not operating in a vacuum. Competitors such as Recursion Pharmaceuticals, Insilico Medicine, and Absci are all deploying AI in various parts of the drug pipeline. But Isomorphic's lineage from DeepMind -- the lab behind AlphaFold, arguably the most significant AI bteakthrough in biology -- gives it a unique advantage in foundational model architecture. The company's integrated end-to-end approach, rather than bolting AI onto existing workflows, represents a bet that the entire paradigm of drug design can be rebuilt from first principles.

The involvement of the UK Sovereign AI Fund is also noteworthy, reflecting government-level interest in retaining AI biotech talent and infrastructure within the United Kingdom at a time when the sector increasingly competes for resources on a global stage.

What to Watch

The key milestone ahead is whether Isomorphic Labs can deliver on its stated goal of entering clinical trials by the end of 2026 -- a target that has already slipped once from a previously stated end-of-2025 deadline. A successful transition from computational predictions to real-world clinical data would validate the core thesis that AI can fundamentally accelerate the drug design process, not just augment it. Investors, pharmaceutical partners, and the broader biotech community will be watching closely to see whether the $2.6 billion bet on AI-first drug design begins to pay dividends at the clinic door.